FDA approves first pill for postpartum depression stating that results can be seen within 3 days, expected to start selling at the end of this year
Foreign news agencies reported that The US Food and Drug Administration (FDA) has approved zuranolone, the nation’s first pill for postpartum depression. It will be distributed under the brand ‘Zurzuvae’ (Zurzuvae).
The FDA states that in the past, treatment for postpartum depression could only be administered intravenously. make suranolone As the first oral postpartum depression treatment, 1 tablet is taken daily for 2 weeks.
Sage Therapeutics and Biogen, the makers of the drug, expect Zur Zuvay will be available in late 2023, but the price has not yet been announced.
According to the FDA, postpartum depression It’s similar to other forms of depression. It can cause the patient to experience depression, loss of energy, thoughts of suicide, diminish their ability to feel joy. or cognitive impairment
“Postnatal depression is a serious and potentially life-threatening condition. causing women to face sadness, guilt In extreme cases, thoughts of hurting yourself or your child will occur,” said Dr. Tiffany Farkeone, chief psychiatrist at the FDA’s Center for Drug Evaluation and Research.
“And because postpartum depression can hinder the bonding between mother and baby, It has consequences for the child’s mental and physical development,” said Dr. Tiffany, adding that access to pill formulations. It will benefit many women dealing with intense, sometimes life-threatening feelings.
In addition, clinical test results show that Suranolone significantly reduced depression within 3 days, and its effects persisted for 4 weeks after the last dose. The most common side effects from taking this drug are drowsiness, dizziness, diarrhea, tiredness, common cold and infections in the urinary tract
The FDA also emphasized that on the side of the drug’s package there is a warning that sur-zuvae can affect driving. and doing other activities that may be dangerous It is also recommended not to drive a car or operate heavy machinery for 12 hours after taking the drug.
Sage Therapeutics and Biogen previously sought approval for the drug for the treatment of major depressive disorder, but the FDA found no evidence that it was effective. and further studies are needed.
2023-08-05 21:15:00
#approves #drug #postpartum #depression #shows #results #days
